Last edition
News about "Pertuza in India for HER2-Positive Breast Cancer"
Alkem Launches Pertuzumab Biosimilar Pertuza in India for HER2-Positive Breast Cancer
Alkem Laboratories has introduced Pertuza, a biosimilar of pertuzumab, in India for the treatment of HER2-positive breast cancer. The drug is supplied as a 420 mg/14 mL injection and is developed and manufactured domestically.
Pertuza In India For HER2-Positive Breast Cancer | 23/09/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members